Bird Rock Bio Files IND Application for Phase 2 Study of Nimacimab for Treatment of Renal Diseases

https://www.prnewswire.com/news-releases/bird-rock-bio-files-ind-application-for-phase-2-study-of-nimacimab-for-treatment-of-renal-diseases-301066663.html

About Bird Rock Bio, Inc.

Backed by leading biotechnology venture investors, Bird Rock Bio's strategy leverages biologic targets with substantial human proof of mechanism for the development of first in class or best in class molecules with strong clinical and commercial differentiation. The Company is focused on developing proprietary antibodies for fibrotic, metabolic and inflammatory diseases. Bird Rock Bio's science team is experienced with translating pioneering research into promising therapeutics with potential deep pharmacoeconomic benefits. For more, visit www.birdrockbio.com.